G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value

被引:11
|
作者
Cho, NH [1 ]
Lim, SY
Kim, YT
Kim, D
Kim, YS
Kim, JW
机构
[1] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Seoul 120749, South Korea
[3] Yonsei Univ, Coll Med, Dept Biostat, Seoul 120749, South Korea
关键词
p53; polymorphism; G2; checkpoint; cyclin B1; p34(cdc2); SnaPshot;
D O I
10.1016/S0090-8258(03)00198-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37degreesC for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4degreesC using mouse anti-human recombinant cyclin B 1 polyclonal antibody or mouse anti-Xenopus p34(cdc2) monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1%) and the control (80.8%) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0%) and the negative (Arg, 88.8%) groups, or between CIN (Arg, 88.2%) and SCC (Arg, 89.1%). Both immunoreactivities to cyclin B and p34(cdc2) were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P 0.0001) between CIN and SCC, being strongly correlated with each other (alpha:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:15 / 22
页数:8
相关论文
共 50 条
  • [31] HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer
    Wu, Yuping
    Liu, Benrong
    Lin, Wenzhi
    Xu, Yunping
    Li, Longyu
    Zhang, Yanling
    Chen, Shangwu
    Xu, Anlong
    JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (04) : 439 - 446
  • [32] HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53
    Yeung, Chi Lam Au
    Tsang, Wing Pui
    Tsang, Tsun Yee
    Co, Ngai Na
    Yau, Pak Lun
    Kwok, Tim Tak
    ONCOLOGY REPORTS, 2010, 24 (06) : 1599 - 1604
  • [33] HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes
    Kawamata, Y
    Mitsuhashi, A
    Unno, Y
    Kado, S
    Shino, Y
    Uesugi, K
    Eguchi, O
    Ishii, J
    Seki, K
    Sekiya, S
    Shirasawa, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 21 (03) : 561 - 567
  • [34] P53 IN COMPLEX WITH DNA IS RESISTANT TO UBIQUITIN-DEPENDENT PROTEOLYSIS IN THE PRESENCE OF HPV-16 E6
    MOLINARI, M
    MILNER, J
    ONCOGENE, 1995, 10 (09) : 1849 - 1854
  • [35] Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16
    Li, W.
    Anderson, R. A.
    ONCOGENE, 2014, 33 (07) : 928 - 932
  • [36] Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 e6 containing SiHa cells
    Huang, HM
    Huang, SY
    Chen, TT
    Chen, JC
    Chiou, CL
    Huang, TM
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (04) : 756 - 765
  • [37] Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16
    W Li
    R A Anderson
    Oncogene, 2014, 33 : 928 - 932
  • [38] HPV-16 E6 downregulation of DNMT1 expression through tumor suppressor p53
    Yeung, Chi Lam Au
    Tsang, Wing Pui
    Tsang, Tsun Yee
    Co, Ngai Na
    Kwok, Tim Tak
    CANCER RESEARCH, 2009, 69
  • [39] Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer
    Heideman, DAM
    Steenbergen, RDM
    van der Torre, J
    Scheffner, M
    Alemany, R
    Gerritsen, WR
    Meijer, CJLM
    Snijders, PJF
    van Beusechem, VW
    MOLECULAR THERAPY, 2005, 12 (06) : 1083 - 1090
  • [40] Human papilloma virus 16 E6 oncoprotein associated with p53 inactivation in colorectal cancer
    Chen, Tan-Hsia
    Huang, Chi-Chou
    Yeh, Kun-Tu
    Chang, Shu-Hau
    Chang, Shih-Wen
    Sung, Wen-Wei
    Cheng, Ya-Wen
    Lee, Huei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (30) : 4051 - 4058